Free Trial

Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis

Centessa Pharmaceuticals logo
$14.53 +0.97 (+7.17%)
As of 12:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Centessa Pharmaceuticals Stock (NASDAQ:CNTA)

Key Stats

Today's Range
$13.67
$14.65
50-Day Range
$11.86
$14.34
52-Week Range
$9.00
$19.09
Volume
702,359 shs
Average Volume
748,298 shs
Market Capitalization
$1.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.89
Consensus Rating
Buy

Company Overview

Centessa Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

CNTA MarketRank™: 

Centessa Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 352nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Centessa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Centessa Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Centessa Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Centessa Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($1.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Centessa Pharmaceuticals is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Centessa Pharmaceuticals is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Centessa Pharmaceuticals has a P/B Ratio of 4.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Centessa Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    5.27% of the float of Centessa Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Centessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Centessa Pharmaceuticals has recently decreased by 15.02%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Centessa Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Centessa Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.27% of the float of Centessa Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Centessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.
  • Change versus previous month

    Short interest in Centessa Pharmaceuticals has recently decreased by 15.02%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Centessa Pharmaceuticals insiders have bought 138.22% more of their company's stock than they have sold. Specifically, they have bought $5,866,687.00 in company stock and sold $2,462,692.00 in company stock.

    • Percentage Held by Insiders

      Only 7.09% of the stock of Centessa Pharmaceuticals is held by insiders.

    • Percentage Held by Institutions

      82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Centessa Pharmaceuticals' insider trading history.
    Receive CNTA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    CNTA Stock News Headlines

    [No Brainer Gold Play]: “Show me a better investment.”
    A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
    CNTA Centessa Pharmaceuticals plc - Seeking Alpha
    Centessa announces clearance of IND for ORX142
    See More Headlines

    CNTA Stock Analysis - Frequently Asked Questions

    Centessa Pharmaceuticals' stock was trading at $16.75 at the start of the year. Since then, CNTA shares have decreased by 14.1% and is now trading at $14.3840.

    Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) released its quarterly earnings data on Monday, May, 12th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.15.

    Centessa Pharmaceuticals (CNTA) raised $285 million in an initial public offering on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

    Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Centessa Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST).

    Company Calendar

    Last Earnings
    5/12/2025
    Today
    7/09/2025
    Next Earnings (Estimated)
    8/12/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - DRUGS
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CNTA
    CIK
    1847903
    Fax
    N/A
    Employees
    200
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $38.00
    Low Price Target
    $6.00
    Potential Upside/Downside
    +96.9%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    10 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$235.76 million
    Pretax Margin
    -1,467.24%

    Debt

    Sales & Book Value

    Annual Sales
    $6.85 million
    Price / Cash Flow
    N/A
    Book Value
    $3.05 per share
    Price / Book
    4.64

    Miscellaneous

    Free Float
    124,086,000
    Market Cap
    $1.89 billion
    Optionable
    Optionable
    Beta
    1.45
    Options Trading Made Easy - Download Now Cover

    Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

    Get This Free Report

    This page (NASDAQ:CNTA) was last updated on 7/9/2025 by MarketBeat.com Staff
    From Our Partners